Metabolic syndrome and resistance to IV thrombolysis in middle cerebral artery ischemic stroke

Neurology

Volumn 71, Issue 3, 2008, Pages 190-195

  Arenillas, J F ^a   Ispierto, L ^a   Millan M ^a   Escudero, D ^a   De La Ossa, N Pérez ^a   Dorado, L ^a   Guerrero, C ^a   Serena, J ^b   Castillo, J ^c   Davalos A ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CITICOLINE; DISUFENTON SODIUM; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DOPPLER ECHOGRAPHY; DRUG INFUSION; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE CEREBRAL ARTERY OCCLUSION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; BRAIN ISCHEMIA; CEREBRAL ARTERY DISEASE; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INFUSIONS, INTRAVENOUS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 48449100653     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000317092.21210.e6     Document Type: Article

References (22)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.
2. Wilson PWF, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112: 3066-3072.
3. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005;28:385-390.
4. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004;27:2444-2449.
5. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109:42-46.
6. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005;36:1366-1371.
7. Chen HJ, Bai CH, Yeh WT, Chiu HC, Pan WH. Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke 2006;37:1060-1064.
8. Kurl S, Laukkanen JA, Niskanen L, et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006;37:806-811.
9. Arenillas JF, Moro MA, Davalos A. The metabolic syndrome and stroke: potential treatment approaches. Stroke 2007;38:2196-2203.
10. Kendall DM, Harmel AP. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance. Am J Manag Care 2002;8:S635-653.
11. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106:286-288.
12. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369: 275-282.
13. Adams HP Jr., Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
14. Grundy SM, Cleeman JI, Daniels SR, et al., American Heart Association, National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
15. Demchuk AM, Burgin WS, Christou I, et al. Thromboly-sis in Brain Ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001;32:89-93.
16. Molina CA, Montaner J, Abilleira S, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2001;32:2821-2827.
17. Ribo M, Montaner J, Molina CA, Arenillas JF, Santama-rina E, Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004;91: 1146-1151.
18. Celik T, Turhan H, Kursaklioglu H, et al. Impact of metabolic syndrome on myocardial perfusion grade after primary percutaneous coronary intervention in patients with acute ST elevation myocardial infarction. Coronary Artery Dis 2006;17:339-343.
19. Ribo M, Molina C, Montaner J, et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 2005;36:1705-1709.
20. Stegenga ME, van der Crabben SN, Levi M, et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006;55: 1807-1812.
21. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among US adults. Obes Res 2003;11:1223-1231.
22. Farin HMF, Abbasi F, Reaven GM. Body mass index and waist circumference correlate to the same degree with insulin-mediated glucose uptake. Metabolism 2005;54: 1323-1328.